Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association

Garcia-Pavia, P; Gonzalez-Lopez, E; Anderson, LJ; Cappelli, F; Damy, T; Fontana, M; Gonzalez-Costello, J; Jurcut, R; Lairez, O; van der Meer, P; Merlo, M; Perlini, S; Bayes-Genis, A

doi:10.1093/eurheartj/ehaf710

Heart failure & cardiomyopathies

Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association

Eur Heart JPublished 7 Oct 2025Clinical consensus statement

Read the original article ↗PubMed

Cite

Recommendations

As issued by the authors

TAVR as the preferred treatment for AS in patients with ATTR-CM

Reference

Issued by: Heart Failure Association of the ESC
Document: Clinical consensus statement
Scope: Non-specific management of transthyretin amyloid cardiomyopathy (ATTR-CM): symptom management and quality of life, volume management, neurohormonal modulation, diuretics and supportive therapies, heart transplantation, mechanical circulatory support, AS in ATTR-CM; advice relies primarily on expert opinion and retrospective studies

Authors: Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M, et al.
All 13 authors
Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M, Gonzalez-Costello J, Jurcut R, Lairez O, van der Meer P, Merlo M, Perlini S, Bayes-Genis A
Journal: European Heart Journal
Published: 7 Oct 2025
DOI: 10.1093/eurheartj/ehaf710
PubMed: 41055898

Topic: Heart failure & cardiomyopathies

Original publication

Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J. Published 7 October 2025. doi:10.1093/eurheartj/ehaf710

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →